Abstract
Background and Aims: Preeclampsia and intrahepatic cholestasis of pregnancy (ICP) are serious complications, which threaten mothers and fetuses with adverse outcomes such as stillbirth or preterm delivery. Labetalol, an alpha-/beta-adrenergic receptor antagonist is recommended in the therapy of hypertension in preeclampsia, however, the treatment was linked to drug-induced liver diseases and ICP. Therefore, we aimed to elucidate the effect of labetalol therapy on bile acid formation and metabolism in an animal model of ICP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.